MMDx Kidney
A New Era of Precision Medicine

The Molecular Microscope® Diagnostic System for Kidney (MMDx® Kidney) combines the technology of molecular phenotyping with the power of big data to deliver objective and reproducible transplant biopsy assessments.

Based on over a decade of research, MMDx Kidney uses artificial intelligence to compare the molecular features of a new biopsy to a reference set, which consists of over 1,200 kidney samples.

The reference set incorporates data from early post-transplant to more than 30 years post-transplant to deliver a more comprehensive understanding of disease states in the transplanted organ.

Concordance to Histological Biopsy Diagnosis

Histopathology scores are the primary tool for diagnosing injury or rejection, but studies show challenges in assigning the diagnosis of ABMR1 and frequent disagreement in histological TCMR diagnosis. Additionally, the quality of the biopsy samples can sometimes impact histology results, rendering the samples unreadable.

MMDx Kidney is not intended to replace histology. Rather, it can be used in addition to a histopathologist’s assessment, especially for the objective assessment of challenging cases.

Variability in Diagnosis with Histopathology

When assessing the same kidney biopsy sample, research shows that only 50% of pathologists will agree on a TCMR diagnosis².
A Comprehensive Biopsy Assessment for All Kidney Transplant Patients

MMDx can be used immediately in post-transplant care for all donor types. The assessment can be applied to a small sample of the existing biopsy. While cortical samples are preferred, the test can read samples containing both medulla and cortex, which may reduce the risk of an “inadequate” biopsy sample and, as a result, the need for a second biopsy.

Advantages of MMDx Kidney

As the latest advancement for the assessment of graft biopsies, MMDx is a convenient and more accurate method for developing the best treatment plan for transplant patients.

- **Actionable data:** Provides objective, quantitative, probabilistic risk assessment
- **Fast turnaround:** Results available within 48 hours after receipt of sample
- **Easily incorporated:** Sample is taken from the existing biopsy and requires sample of 3-5 mm
- **Efficient process:** Simply put biopsied tissue into the provided tube (containing RNAlater®) and ship at room temperature

New Studies on Molecular Assessment for Graft Function

In kidney patients with chronic active antibody-mediated rejection (caABMR) and a high degree of chronicity, molecular evidence of rejection has been used to track responses to immunosuppressive therapies and identify response to treatment, as evidenced by improved inflammation³.

Inflammation in areas of atrophy-fibrosis (i-IFTA) has shown to be associated with increased risk of failure in kidney biopsies. A recent study has concluded that i-IFTA in indication biopsies reflect current or ongoing parenchymal injury, either with TCMR or (more commonly) with concomitant ABMR⁴.

MMDx Kidney has demonstrated accuracy and reproducibility in kidney biopsy assessment with minimal inter-observer disagreement in reporting. As a result, MMDx may be particularly valuable in cases when pathology results are borderline or suspicious⁵.

References


Learn more at [go.1lambda.com/mmdxkidney](go.1lambda.com/mmdxkidney) or email us at [1lambda-mmdx@thermofisher.com](1lambda-mmdx@thermofisher.com)

MMDx and Molecular Microscope are registered trademarks of Transcriptome Sciences Inc. RNAlater is a registered trademark of Ambion, Inc.

MMDx Heart and MMDx Kidney are tests that were developed and validated by Kashi Clinical Laboratories, Inc. The laboratory developed tests are used for clinical purposes by the CLIA-certified laboratory performing the test. These tests have not been cleared or approved by the US FDA or CE marked in the EU as an in vitro diagnostic test.

© 2021 Thermo Fisher Scientific. All rights reserved.